Knockdown of MRN complex decreases HBV cccDNA level. by Kaitao Zhao (3617825)

The Date. by Chengyuan Hao (21615653)

“…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”

Variation curve of the extreme temperature index. by Chengyuan Hao (21615653)

“…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”

The mean number of the emerged <i>D. melanogaster</i> adults. Mean number (±SE) of emerged adults and average percentage (±SE) of the residual fertility at the different treatment... by Flavia Cerasti (21655934)

Functional analysis of a <i>kh</i>^<i>w</i> mutant mosquitoes. by Si Yu Zhao (19544793)

CIE L*a*b* color space values of urine measured by a spectrophotometer showed significant correlations with Uturb as observed through visual examination. by Jingnan Liu (2219029)

“…<p>(A) The increase in Uturb was significantly correlated with a decrease in urine brightness (L*). …”

Changes in the color parameters of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) in different feed treatment groups^a over a 56-day period (mean ± SD, <i>n</i> = 20). by Wei-Wei Hou (3405947)

Quantification of bacterial adhesion revealed a significant decrease in the adhesion of <i>S. aureus</i>, <i>S. epidermidis</i>, and <i>P. aeruginosa</i> on blotted corneas of mice treated with 0.5% bupivacaine (BUP) combined with topical (TOP) application, following subconjunctival injection (SCI) of CGRP, 24 hours before the final BUP treatment (day 14) and again one hour prior to the final bupivacaine injection on day 15. by Ananya Datta (19932144)

Maximum likelihood estimates of trans-log mean stochastic function. by James Anaba Akolgo (14129379)

Predictors used in the modelling analysis. The ‘Snail count’ model refers to the Generalised Linear Mixed Model (GLMM) used to model snail counts, ‘Prevalence’ refers to the diseas... by Roland Proud (11764892)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects: